We are live on ! Find out more
ASND icon

Ascendis Pharma A/S
ASND

189 hedge funds and large institutions have $9.19B invested in Ascendis Pharma A/S in 2024 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 73 increasing their positions, 51 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 51

21% more capital invested

Capital invested by funds: $7.61B → $9.19B (+$1.58B)

18% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 33

2% more funds holding

Funds holding: 185 → 189 (+4)

0% more funds holding in top 10

Funds holding in top 10: 16 → 16 (0)

0.31% less ownership

Funds ownership: 105.66% → 105.35% (-0.31%)

7% less call options, than puts

Call options by funds: $48.3M | Put options by funds: $51.8M

Holders
189
Holders Change
+4
Holders Change %
+2.16%
% of All Funds
2.72%
Holding in Top 10
16
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.23%
New
39
Increased
73
Reduced
51
Closed
33
Calls
$48.3M
Puts
$51.8M
Net Calls
-$3.49M
Net Calls Change
-$9.66M

Top Buyers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
+$131M
2
Millennium Management
Millennium Management
New York
+$48.5M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$48.1M
4
Citadel Advisors
Citadel Advisors
Florida
+$40.8M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$33.5M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$203M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$71.7M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$32.5M
4
TCM
TimesSquare Capital Management
New York
-$31M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$25.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
LSA
176
Leonteq Securities AG
Switzerland
$11.8K -$23.8K -167 -68%
SAM
177
Smartleaf Asset Management
Massachusetts
$9.35K – – –
EC
178
Elequin Capital
New York
$7.56K +$7.14K +50 New
BIA
179
Bell Investment Advisors
California
$7.11K +$571 +4 +9%
PTC
180
Private Trust Company
Ohio
$5.9K -$714 -5 -11%
WTA
181
Washington Trust Advisors
Massachusetts
$5.75K – – –
QC
182
Quent Capital
New York
$5.74K – – –
HCM
183
Hollencrest Capital Management
California
$5.74K +$5.42K +38 New
BWL
184
Bogart Wealth LLC
Virginia
$5.14K – – –
Walleye Capital
185
Walleye Capital
New York
$4.38K -$162K -1,133 -98%
HI
186
Hoey Investments
Pennsylvania
$3.63K – – –
EBA
187
Eagle Bay Advisors
New York
$3.52K – – –
BAM
188
Bellevue Asset Management
Washington
$2.27K – – –
TSMHT
189
Thurston Springer Miller Herd & Titak
Indiana
$2.12K +$2K +14 New
EAM
190
Eventide Asset Management
Massachusetts
– -$22.8M -180,857 Closed
CCM
191
Camber Capital Management
Massachusetts
– -$20.8M -165,000 Closed
PA
192
Perceptive Advisors
New York
– -$16.6M -132,176 Closed
TCM
193
Tang Capital Management
California
– -$8.82M -70,000 Closed
CAPTRUST Financial Advisors
194
CAPTRUST Financial Advisors
North Carolina
– -$3.53M -28,051 Closed
AAA
195
Affinity Asset Advisors
New York
– -$2.52M -20,000 Closed
GTC
196
Ghost Tree Capital
New York
– -$2.52M -20,000 Closed
RA
197
Rosalind Advisors
Ontario, Canada
– -$2.12M -16,800 Closed
HT
198
HAP Trading
New York
– -$1.55M -12,299 Closed
RJFSA
199
Raymond James Financial Services Advisors
Florida
– -$1.04M -8,224 Closed
VFA
200
Values First Advisors
Tennessee
– -$988K -7,844 Closed
5 6 7
8
9

ASND Hedge Fund Activity: Q1 2024 in Review

189 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q1 2024, worth a combined $9.19B — up 21% from $7.61B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new ASND positions and 33 closed out — a net gain of 6 holders — while 73 added to existing stakes and 51 trimmed.

The largest buyer was Franklin Resources, adding an estimated $131M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $203M.

  • 189 institutional investors held Ascendis Pharma A/S (ASND) as of Q1 2024, up from 185 in Q4 2023.
  • Funds reported $9.19B of Ascendis Pharma A/S stock for Q1 2024, up 21% quarter-over-quarter.
  • 39 funds opened new Ascendis Pharma A/S positions in Q1 2024 and 33 closed out, a net change of +6 holders.
  • The largest Ascendis Pharma A/S buyer in Q1 2024 was Franklin Resources, an estimated $131M added.
  • The largest Ascendis Pharma A/S seller in Q1 2024 was T. Rowe Price Investment Management, an estimated $203M sold.

Based on aggregated 13F filings for Q1 2024.